Recently, Tianjin Pharmaceutical Co., Ltd. received an establishment inspection report (EIR) issued by the U.S. FDA. The report indicates that the company's production site (No. 19, Xinyejiu Street, West Zone, Tianjin Economic-Technological Development Area) has passed the CGMP on-site inspection.

Tianjin Pharmaceutical Co., Ltd. underwent a CGMP (Current Good Manufacturing Practice) on-site inspection by the U.S. Food and Drug Administration (hereinafter referred to as "FDA") from December 9 to December 13, 2024.

Passing the on-site inspection by the US FDA demonstrates that Tianjin Pharmaceutical Group meets FDA requirements in terms of its drug quality management system and production facilities and equipment, providing a solid guarantee for the company's continued expansion in the international market for active pharmaceutical ingredients. In the future, Tianjin Pharmaceutical Group will continue to improve its quality system, operate efficiently in accordance with international quality management system requirements, and continuously enhance the company's overall competitiveness.

Manuscript: Board Office of Tianjin Pharmaceutical Group